Optimizing the use of angiogenesis inhibitor in neovascular age-related macular degeneration
Abstract
The purpose of the study was to estimate the effectiveness of using ranibizumab in combination with medotilin drug in the treatment of neovascular age-related macular degeneration (AMD). Material and methods. 50 patients (65 eyes) aged 41 to 88 (ave. 68.5 ± 0.98 years) with neovascular AMD were followed-up. All patients were assigned treatment consisting of three intravitreal ranibizumab injections with an interval of 1 month between injections. Of these, 25 patients (34 eyes) were additionally given 4 ml of medotilin intramuscularly once a day for 10 days. Results. Combined treatment with ranibizumab and medotilin showed a statistically significant improvement of functional parameters: visual acuity, light sensitivity and flicker ERG as compared to the control group. Conclusion. Medotilin, which has neuroprotective action, enhances the effect of angiogenesis inhibitors drugs in all forms of neovascular AMD and promotes statistically significant increase of the functional condition of the central retina area, which is confirmed by electroretinography data // Russian Ophthalmological Journal, 2017; 1: 9-14. doi: 10.21516/2072-0076-2017-10-1-9-14.